Compare Citius Pharmaceuticals Inc (CTXR) vs Etsy Inc (ETSY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Etsy Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.77 (market cap $20.01M), while Etsy Inc trades at $79.73 (market cap $7.29B). The key difference: Etsy Inc is far larger — about 364.3× Citius Pharmaceuticals Inc's market cap, and Etsy Inc is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| CTXR | ETSY | |
|---|---|---|
Market Cap | $20.01M | $7.29B |
Sector | Health | Consumer Cyclical |
52-Week High | $1.82 | $86.47 |
52-Week Low | $0.48 | $44.05 |
Enterprise Value | $16.23M | $9.25B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR is trading at $0.765, up 13.0% in the past 24 hours, with a bullish technical signal from moving averages. The company shows strong analyst support with 83% buy ratings but faces significant financial challenges including negative earnings, a -823.34% net income margin, and consecutive quarterly EPS misses. Recent news highlights expansion of LYMPHIR cancer treatment commercialization with 78% quarterly growth in new institutional accounts.
While technical indicators suggest near-term upside potential and analyst sentiment remains positive, fundamental weaknesses including substantial losses and negative cash flow from operations present significant investment risks. The company's ability to achieve profitability through its oncology drug commercialization will determine long-term shareholder value creation.
ETSY trades at $79.53, down 1.08% on the day, with a bearish technical signal but strong recent earnings beats. The company reported Q2 2026 EPS of $0.98, beating expectations, and announced a $2 billion share buyback alongside a 12% workforce reduction to boost efficiency. Revenue trends show modest growth, with 2025 revenue at $2.88 billion, though net income margin declined to 5.65% from prior years.
Outlook is mixed: analyst consensus is a Buy with a $85.71 price target, citing GMS growth and cost initiatives, but risks include high debt, margin pressure, and competitive threats. The stock's current price near support at $78 offers potential upside if operational improvements sustain.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Etsy Inc
Etsy operates a top-10 e-commerce marketplace operator in the U.S. and the U.K., with sizable operations in Germany, France, Australia, and Canada. The firm dominates an interesting niche, connecting buyers and sellers through its online market to exchange vintage and craft goods. With $13.5 billion in 2021 consolidated gross merchandise volume, the firm has cemented itself as one of the largest players in a quickly growing space, generating revenue from listing fees, commissions on sold items, advertising services, payment processing, and shipping labels. As of the end of 2021, the firm connected more than 96 million buyers and more than 7.5 million sellers on its marketplace properties: Etsy, Reverb (musical equipment), Elo7 (crafts in Brazil), and Depop (clothing resale).
Read more on ETSY →
